Certara Q3 2026: Software Momentum Keeps the Engine Warm as 2026 Revenue Range Narrows

Ticker: CERT (Nasdaq: CERT) • EPS context and EPS consensus notes appear as analysts parse the continuing-operations figures; revenue forecast shifts are the centerpiece of the guidance.

Certara, Inc. reports its third quarter of 2026 from continuing operations with a revenue print of $94.9 million, a split that tells a familiar story: software revenue is the growth engine, up 11% year over year to $48.8 million, while Services revenue eases to $46.1 million, down 2%. The company posted a net loss from continuing operations of $3.6 million, an improvement from the $4.8 million loss a year ago, and adjusted EBITDA of $30.2 million with a margin of 31.8%. In plain English for the balance sheet and cash people: cash on hand rose to $214.9 million after the quarter, and the company generated $30.7 million of cash from continuing operations in the period. All of this sits under a revised 2026 revenue growth range of 2%–3% as nine months of results inform the outlook.

Revenue mix: software savings and service adjustments

Revenue was $94.9 million, up from $90.9 million in Q3 2025—a 4% lift. Software revenue advanced to $48.8 million from $43.8 million a year earlier, an 11% increase that underscores software’s central role in Certara’s growth narrative. Services revenue, by contrast, declined to $46.1 million from $47.1 million, marking a 2% decrease. The mix shift toward software is the kind of structural change investors tend to notice: recurring revenue streams with margin leverage tend to be more resilient in a market where customers increasingly seek platform-based solutions for drug development support.

Margins improve as operating actions bite

On the profitability front, Certara reported net loss from continuing operations of $3.6 million, an improvement versus the $4.8 million loss in the prior-year period. Adjusted EBITDA came in at $30.2 million, with a margin of 31.8%—a gain of more than 370 basis points versus the second quarter. The company also highlighted cash generation in the quarter, with $30.7 million of cash from continuing operations and a year-to-date cash balance of $214.9 million. The math here matters: improved margins coupled with steady cash generation support a cautious but improving earnings trajectory, even as the GAAP bottom line remains sensitive to discontinued operations and one-time items.

Guidance tightens: a 2026 revenue trajectory that looks more defined

With nine months in the books, Certara narrowed its full-year 2026 revenue growth range to 2%–3%. This move is telling: management is anchoring expectations in the software-led growth story and the continued discipline of operating costs. The stance implies that investors should watch for the EPS trajectory to align with the refined revenue outlook, and any EPS surprise (positive or negative) would hinge on the degree to which software momentum sustains and services stabilizes or improves.

In the same breath, the firm announced a strategic leadership change that could influence product and portfolio choices: Grant Peterson will assume the role of Chief Product Officer, effective November 2. Peterson’s background—spanning Conga and DocuSign across product leadership and technology—suggests Certara intends to sharpen its product roadmap, prioritize portfolio investments, and accelerate growth vectors informed by customer feedback and the broader tech ecosystem. This is not a cosmetic hire; it’s a signal that Certara aims to convert software momentum into differentiated offerings and broader adoption across customers’ development pipelines.

Operational framing: continuing vs. discontinued operations

The company notes that results from the Regulatory and Medical Writing business are reported as discontinued operations. The discussion in this earnings release centers on continuing operations, which means any assessment of EPS (or its lack thereof) should be anchored in the ongoing core business. For peers in the model-informed drug development space, this separation underscores the importance of sustaining a core software engine while managing legacy segments that do not directly feed the current growth narrative.

What this could portend for Certara and sector peers

The Q3 mix matters. A double-digit software growth rate, even as overall revenue remains modest, tends to elevate the quality of earnings via higher gross margins and more predictable cash generation. If Certara sustains software momentum and the new product leadership translates into a stronger product portfolio, the stock could benefit from a higher multiple justified by “platform” growth rather than one-off project work. The EPS conversation will hinge on how quickly the company can convert operating leverage into GAAP earnings, especially as discontinued operations exit the narrative and as any one-time costs linked to leadership changes fade.

From a sector perspective, Certara’s trajectory—software-led growth, disciplined cost management, and a pivot-focused product leadership hire—is a playbook several peers could emulate. In a market where pharma R&D spend remains robust but efficiency demands rise, sustained software adoption and a move toward platform solutions could become a differentiator. If other model-informed and simulation-driven software providers show similar software mix improvements, the “earnings surprise” potential could shift from a rare event to a recurring theme—though the bar remains high, and timing matters for revenue recognition cycles and customer renewals.

Conclusion: Certara’s quiet engine hums, with a new product captain at the helm

Certara’s Q3 2026 results reinforce the company’s narrative: software revenue is the engine, cash flow is the ballast, and management’s guidance is a pragmatic tightening of expectations. The appointment of Grant Peterson signals a deliberate push to translate software momentum into new products and broader portfolio investments, potentially lifting the company’s EPS trajectory over the medium term. For investors watching the sector, Certara’s path suggests that a well-executed software-centric model in drug development tools can coexist with disciplined cost management, producing a steadier cadence of results—even when not every line item on the income statement hugs a perfect EPS target on the first pass.

The company will host a conference call and webcast today at 8:30 a.m. ET to discuss these results further, a moment to gauge whether the market’s focus on the revenue forecast and the potential for an earnings surprise becomes a little more oriented toward the software engine Certara is betting on.